Health
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A – Science
SARS-CoV-2 viral proteins interact with the eukaryotic translation machinery and inhibitors of translation have potent antiviral effects. Here we report that the…
Abstract
SARS-CoV-2 viral proteins interact with the eukaryotic translation machinery and inhibitors of translation have potent antiviral effects. Here we report that the drug plitidepsin (aplidin), which has limited clinical approval, possesses antiviral activity (IC90 = 0.88 nM) 27.5-fold more potent than remdesivir against SARS-CoV-2 in vitro, with limited toxicity in cell culture. Through the use of a drug resistant mutant, we show that the antiviral activity of plitidepsin against SARS-CoV-2…
-
General22 hours agoEveryday AI use brings a hidden climate cost
-
Noosa News17 hours agoThe Laundry Lady secures $1M to fuel international expansion
-
Noosa News14 hours agoTruffle growers say rare delicacy is worth its $3,500 per kilo expense
-
Noosa News14 hours agoHomicide investigation underway after woman found dead in north Brisbane